When do you consider including Rituximab into the treatment regimen for a pediatric or AYA patient with intermediate and advanced-stage nodular lymphocyte-predominant Hodgkin lymphoma?

First, I would want to make sure the diagnosis is correct as advanced stage NLPHL is extremely rare. T-cell rich B-cell lymphoma can look identical histologically. Either way, R-CHOP therapy is good therapy for both.